-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Cszj6yXHN2Rz8qvMy0GT41GMEU156DPpMYcg7htmIqZR5l3aZmCae49LudAkMzCN 1Q849xfDHvHbnvi2fbcgPw== 0001179110-06-005360.txt : 20060302 0001179110-06-005360.hdr.sgml : 20060302 20060302181635 ACCESSION NUMBER: 0001179110-06-005360 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20060228 FILED AS OF DATE: 20060302 DATE AS OF CHANGE: 20060302 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LIPID SCIENCES INC/ CENTRAL INDEX KEY: 0000071478 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 430433090 STATE OF INCORPORATION: AZ FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7068 KOLL CENTER PARKWAY STREET 2: SUITE 401 CITY: PLEASANTON STATE: CA ZIP: 94566 BUSINESS PHONE: 925-249-4000 MAIL ADDRESS: STREET 1: 7068 KOLL CENTER PARKWAY STREET 2: SUITE 401 CITY: PLEASANTON STATE: CA ZIP: 94566 FORMER COMPANY: FORMER CONFORMED NAME: NZ CORP DATE OF NAME CHANGE: 20000810 FORMER COMPANY: FORMER CONFORMED NAME: NEW MEXICO & ARIZONA LAND CO DATE OF NAME CHANGE: 19920703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: RICHARDSON DALE L CENTRAL INDEX KEY: 0001162527 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-00497 FILM NUMBER: 06661255 BUSINESS ADDRESS: STREET 1: 7068 KOLL CENTER PARKWAY STREET 2: SUITE 401 CITY: PLEASANTON STATE: CA ZIP: 94566 BUSINESS PHONE: 9252494000 4 1 edgar.xml FORM 4 - X0202 4 2006-02-28 0 0000071478 LIPID SCIENCES INC/ LIPD 0001162527 RICHARDSON DALE L 7068 KOLL CENTER PARKWAY, SUITE 401 PLEASANTON CA 94566-3111 0 1 0 0 VP, Business Development Stock Option (right to buy) 2.64 2006-02-28 4 A 0 28044 2.64 A 2016-02-27 Common Stock 28044 352528 D Vesting of the options will be subject to the condition of the occurrence of the treatment of the first patient in Lipid Sciences, Inc.'s contemplated clinical trial at Medstar Institute in Washington, D.C. and will be further subject to vesting over a three-year term in one-third increments beginning on the first anniversary of the grant date and on the second and third anniversary thereafter. By Sandra Gardiner, as Attorney-in-Fact on behalf of Dale L. Richardson, Vice President of Business Development 2006-03-02 -----END PRIVACY-ENHANCED MESSAGE-----